Review article: consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases. Issue 11 (13th October 2017)

• Record Type: Journal Article
• Authors: Mitrev, N.; Vande Casteele, N.; Seow, C. H.; Andrews, J. M.; Connor, S. J.; Moore, G. T.; Barclay, M.; Begun, J.; Bryant, R.; Chan, W.; Corte, C.; Ghaly, S.; Lemberg, D. A.; Kariyawasam, V.; Lewindon, P.; Martin, J.; Mountifield, R.; Radford‐Smith, G.; Slobodian, P.; Sparrow, M.; Toong, C.; van Langenberg, D.; Ward, M. G.; Leong, R. W.
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 46:Issue 11/12(2017)
• Page Start: 1037
• Page End: 1053
• Publication Date: 2017-10-13
• Subjects: Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.14368
• Languages: English
• ISSNs: 0269-2813

Abstract

Summary: Background: Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes. Consensus statements based on current evidence will help the development of treatment guidelines. Aim: To develop evidence‐based consensus statements for TDM‐guided anti‐TNF therapy in IBD. Methods: A committee of 25 Australian and international experts was assembled. The initial draft statements were produced following a systematic literature search. A modified Delphi technique was used with 3 iterations. Statements were modified according to anonymous voting and feedback at each iteration. Statements with 80% agreement without or with minor reservation were accepted. Results: 22/24 statements met criteria for consensus. For anti‐TNF agents, TDM should be performed upon treatment failure, following successful induction, when contemplating a drug holiday and periodically in clinical remission only when results would change management. To achieve clinical remission in luminal IBD, infliximab and adalimumab trough concentrations in the range of 3‐8 and 5‐12 μg/mL, respectively, were deemed appropriate. The range may differ for different disease phenotypes or treatment endpoints—such as fistulising disease or to achieve mucosal healing. In treatment failure, TDM may identify mechanisms to guide subsequent decision‐making. In stable clinical response, TDM‐guided dosing may avoid future relapse. Data indicate drug‐tolerant anti‐drug antibody assays do not offer an advantage over drug‐sensitive assays. Further data are required prior to recommending TDM for non‐anti‐TNF biological agents. Conclusion: Consensus statements support the role of TDM in optimising anti‐TNF agents to treat IBD, especially in situations of treatment failure.